From 2007 to 2014 I wrote one of the most read blogs in the English language. Published here at JohnShore.com and on The Huffington Post, my spirituality/advice/advocacy/humor writings received over 20 million views, and generated (on JohnShore.com alone) some 300,000 comments.
I retired my blog in late 2014 in order to write my first novel, which will be available in early 2019.
In October of 2016 I started writing a weekly advice column for The Asheville Citizen-Times (the major daily newspaper of Asheville, NC, and part of the USA Today Network). Appearing online on Tuesdays and in the paper’s pull-out entertainment section (“SCENE”) on Fridays, Ask John is one of the Citizen-Times’ two most popular columns.
From April 2016 to November 2017, I wrote Ashes to Asheville, the first real-time weekly serial novel ever published on the website of a major daily newspaper. You can read Ashes on the Citizen-Times website, or here on this site. It’s also available as a podcast via iTunes or its Libsyn page. The Citizen-Times’ article introducing Ashes to its readers is here.
In January 2016 I finished a month-long Kickstarter campaign for my debut novel. The campaign raised more money for any debut novel in Kickstarter’s history. That novel will finally be out in early 2019. (Its lateness has everything to do with the extremely unexpected costs my wife and I incurred during the building of our first home—a home about which you can read a bit in an article I wrote for the Asheville Citizen-Times, Home of the Week: Affordable and Green in West Asheville. Thankfully, the backers of my KS campaign have been phenomenally patient and gracious to me during the book’s mortifyingly long delay.)
You can read more about my writing and editing career here.
Besides the advice column, these days I’m mainly keeping in touch through my monthly newsletter, to which you can subscribe below. I use MailChimp for this, so you can be sure my newsletter is safe, secure, and won’t ever result in any spam or ads. Unsubscribe with one click of your mouse.